Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + Chemo Neoadjuvant for NSCLC with Driver Mutations
NCT06299371Phase 2Not yet recruiting
- Sponsor
- Liaoning Medical Center
- Start
- Apr 2024
- Primary completion
- Apr 2026
- Modality
- Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of adebrelimab in non-small cell lung cancer (NSCLC), sponsored by Liaoning Medical Center. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06299371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06299371.